Literature DB >> 2310182

Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility.

M C Stinson1, M S Galanek, A M Ducatman, F X Masse, D R Kuritzkes.   

Abstract

A method is described for autoclaving low levels of solid infectious, radioactive waste. The method permits steam penetration to inactivate biologic waste, while any volatile radioactive compounds generated during the autoclave process are absorbed. Inactivation of radiolabeled infectious waste has been problematic because the usual sterilization techniques result in unacceptable radiation handling practices. If autoclaved under the usual conditions, there exists a high probability of volatilization or release of radioisotopes from the waste. This results in the radioactive contamination of the autoclave and the laboratory area where steam is released from the autoclave. Our results provide a practical method to inactivate and dispose of infectious radioactive waste. For our research, Bacillus pumilus spore strips and vaccinia virus were used as more heat-resistant surrogates of the human immunodeficiency virus (HIV). These surrogates were used because HIV is difficult to grow under most conditions and is less heat tolerant than the surrogates. In addition, B. pumilus has defined cell death values, whereas such values have not been established for HIV. Both B. pumilus and vaccinia virus are less hazardous to work with. The autoclave method is time efficient and can be performed by laboratory personnel with minimal handling of the waste. Furthermore, waste site handlers are able to visually inspect the solid waste containers and ascertain that inactivation procedures have been implemented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310182      PMCID: PMC183304          DOI: 10.1128/aem.56.1.264-268.1990

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  10 in total

1.  Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments.

Authors:  L Resnick; K Veren; S Z Salahuddin; S Tondreau; P D Markham
Journal:  JAMA       Date:  1986-04-11       Impact factor: 56.272

Review 2.  The epidemiology of AIDS in the U.S.

Authors:  W L Heyward; J W Curran
Journal:  Sci Am       Date:  1988-10       Impact factor: 2.142

3.  Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus.

Authors:  L S Martin; J S McDougal; S L Loskoski
Journal:  J Infect Dis       Date:  1985-08       Impact factor: 5.226

4.  Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systems.

Authors:  S Harada; H Yoshiyama; N Yamamoto
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

5.  Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers.

Authors:  S H Weiss; J J Goedert; S Gartner; M Popovic; D Waters; P Markham; F di Marzo Veronese; M H Gail; W E Barkley; J Gibbons
Journal:  Science       Date:  1988-01-01       Impact factor: 47.728

6.  Replacing the 'soft' touch with the safe touch.

Authors:  W Atkinson
Journal:  Occup Health Saf       Date:  1989-01

7.  Inactivation by wet and dry heat of AIDS-associated retroviruses during factor VIII purification from plasma.

Authors:  J A Levy; G A Mitra; M F Wong; M M Mozen
Journal:  Lancet       Date:  1985-06-22       Impact factor: 79.321

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  HTLV-III in the semen and blood of a healthy homosexual man.

Authors:  D D Ho; R T Schooley; T R Rota; J C Kaplan; T Flynn; S Z Salahuddin; M A Gonda; M S Hirsch
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.